治疗难治的血管异常 (SIVA) 的sirolimus治疗:一个开放的标签,单臂,多中心,前性试验
Michio Ozeki1,2, Saori Endo1, Shiho Yasue1
1Department of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
概括
在超过一半的患有难治性血管异常 (VAs) 的患者中,sirolimus治疗显示出部分放射性反应. 这种药物可以改善VA患者的症状和日常生活活动.
科学领域:
- 血管医学 血管医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 吸收性血管异常 (VA) 由于严重的症状和不良预后,存在重大挑战.
- 新的治疗策略对于管理这些复杂的疾病至关重要.
研究的目的:
- 评估西洛斯在治疗各种类型血管异常患者中的疗效和安全性.
- 评估西洛斯对放射反应,症状和生活质量的影响.
主要方法:
- 一个前性的,开放的,单臂的,多中心的试验,涉及13名VA患者.
- 每天服用口服西洛利斯,目标最低度为5-15 ng/mL.
- 在52周内评估放射性反应,临床症状,生活质量和安全性.
主要成果:
- 在24周53.8%的患者和12周61.5%的患者观察到部分放射性反应.
- 皮肤病变,血液凝固和日常生活活动的改善.
- 常见的不良事件包括口腔炎,皮肤炎,腹和发烧.
结论:
- 西洛利斯显示出降低血管异常组织体积的潜力.
- 该药物可以提供症状缓解,并改善VA患者的日常生活活动.
- 进一步的研究是有必要的,以优化西洛利木斯治疗VA.
更多相关视频
相关概念视频
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...